Excessive sweating of palms and armpits (hyperhidrosis)
Innotox is completely ready for use, no need to mix with saline water. It has a low degree of diffusion prevents the influence of toxin on the tissues adjacent to the correction area. This product is Not temperature sensitive and is stable up to 82 degrees. The result of the procedure lasts up to 8 months.
- Results take 7-14 days after each treatment. Allow 2 weeks between each treatment.
***This product is not eligible for Free Shipping*** We place the products in a cool shield thermal bubble packaging with ice packs so that vial remains to be stored at a low temperature. The volume of ice is carefully calculated, based on the shipping destination and the number of products to ensure that the temperature is well kept until the point of delivery.
- Unlike other botulinum toxins, Innotox can be stored and transported at room temperature, it is heat resistant up to 28 degrees Celsius, 82 Fahrenheit.
- Recommended to store in the fridge if not in immediate use for longer shelve life.
- Open vial can be stored in the fridge up to two weeks.
Expiration: Indicated on product
The product is manufactured by Medytox Inc. in the form of a solution in vials, one in a package. The basic component is botulotoxin type A Clostridium botulinum in the amount of 50 units.
Innotox is predicted by the same Hall strain of C.botulinum as Neuronox and Botox. The molecular weight of Innotox analyzed using size exclusion SE-HPLC is approximately 900 kDa. Which is highly comparable to those of Neuronox and Glowtox.
Another key characteristic of Innotox is that it excludes the use of substances of animal origin in the manufacturing process to eliminate the risks associated with animal-based proteins. Moreover, it excludes human serum albumin as an excipient of the final product to avoid any risk associated with diseases of human blood origin. Instead it contains methionine and polysorbate as a stabilizer.
The safety and efficacy of Innotox and Glowtox were compared at a 1:1 dose ratio for treating glabellar lines in a double-blinded, randomized, phase III multi center study with 168 subjects. The patients, aged 20 to 65 years with moderate-to-severe glabellar lines, were randomly treated with 20U of Innotox or Glowtox and subsequently assessed by blinded investigators. The improvement rate at both maximum frown and rest was not significantly different between the Innotox and Glowtox groups. No severe adverse drug reactions were observed.